1. Home
  2. SHFS vs OGEN Comparison

SHFS vs OGEN Comparison

Compare SHFS & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SHF Holdings Inc.

SHFS

SHF Holdings Inc.

HOLD

Current Price

$0.24

Market Cap

2.7M

Sector

Finance

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.61

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHFS
OGEN
Founded
2015
1996
Country
United States
United States
Employees
41
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
SHFS
OGEN
Price
$0.24
$0.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.4M
49.0K
Earning Date
04-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.50
52 Week High
$9.18
$4.00

Technical Indicators

Market Signals
Indicator
SHFS
OGEN
Relative Strength Index (RSI) 26.80 34.89
Support Level N/A N/A
Resistance Level $0.96 $0.65
Average True Range (ATR) 0.06 0.03
MACD -0.00 -0.00
Stochastic Oscillator 5.87 0.00

Price Performance

Historical Comparison
SHFS
OGEN

About SHFS SHF Holdings Inc.

SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: